Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 (Ulotaront) Open-Label Extension in Generalized Anxiety Disorder
NCT07786454Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in generalized anxiety disorder (GAD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2026; status: recruiting.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07786454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786454.